PCOS and GLP-1 Medicines in India: What the Evidence Says

GLP-1 medicines can help women with PCOS who carry extra weight to lose it, and the 2023 international PCOS guideline says they could be considered alongside lifestyle changes for adults with PCOS and higher weight. The evidence in PCOS itself is still limited: trials show modest weight and BMI loss, with weaker and less certain evidence on periods, testosterone and fertility. They are not for women who are pregnant or trying to conceive, and the guideline asks for reliable contraception while taking them.

Why "just lose weight" was never the full answer

PCOS is not a weight problem with some hormone symptoms attached. For many women it is a metabolic condition, and insulin resistance sits close to its centre. Higher insulin pushes the ovaries to make more androgens, which disturbs periods and drives acne and facial hair, and it makes weight easier to gain and harder to lose. Telling someone in that cycle to eat less and walk more is not wrong, but on its own it is often not enough.

Indian data shows how much is at stake. In the ICMR-funded study, most women with PCOS had at least one metabolic abnormality: 91.9% had abnormal blood fats, 24.9% met the criteria for metabolic syndrome, and 9.1% already had impaired glucose tolerance (Ganie et al., 2024). This is why a PCOS check-up should include blood sugar, HbA1c and a lipid profile, not just an ultrasound. If your sugars are already high, read why your diabetologist should be involved before any weight-loss medicine.

What the 2023 guideline says

The International Evidence-based Guideline for the Assessment and Management of PCOS, updated in 2023 and published in several journals at once, is the reference most PCOS specialists use. On medicines for weight, it says:

• GLP-1 medicines, including liraglutide and semaglutide, could be considered alongside active lifestyle changes for adults with PCOS and higher weight, as for the general population.
• Women taking them should use effective contraception when pregnancy is possible, because safety data in pregnancy are lacking.
• Doses should be increased gradually to reduce stomach side effects.
• Decisions should weigh the possible need for long-term use, since weight often returns after stopping, and long-term safety data are still limited.
• Separately, metformin should be considered for adults with PCOS and a BMI of 25 or more, for weight and metabolic outcomes.

One word in the first line deserves attention: "could". The GLP-1 recommendation is a consensus recommendation, which means experts agreed on it because there was not enough PCOS-specific trial evidence for a stronger one (guideline full text).

What the trials in PCOS show

Most PCOS trials so far are small and short. The large trials of weekly semaglutide and tirzepatide were run in adults with obesity in general and were not designed to measure PCOS outcomes. The 2026 review put it plainly: GLP-1 medicines are associated with modest short-term weight loss in women with PCOS, while the benefits for metabolic, reproductive and psychological outcomes remain uncertain because the data are of low quality. Better trials are needed on periods, skin, hair and fertility.

Pregnancy, fertility and contraception

This is the part that matters most for many women with PCOS, because weight loss can make ovulation more regular and pregnancy more likely, sometimes sooner than expected.

• Planning a pregnancy: the semaglutide label advises stopping at least 2 months before a planned pregnancy, because the medicine stays in the body for weeks (US prescribing information). The tirzepatide label advises stopping when a pregnancy is recognised (US prescribing information). Plan the timing with your doctor.
• On the pill? Tirzepatide can make oral contraceptive pills less reliable. Its label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase (US prescribing information).
• Trying for a baby with fertility treatment? Weight loss before IVF is a separate conversation with your fertility specialist. Our guide to weight loss before IVF covers it.

Semaglutide or tirzepatide for PCOS?

No trial has compared the two head to head in women with PCOS. In adults with obesity generally, tirzepatide produced more weight loss than semaglutide in the one head-to-head trial, and India's 2025 obesity guideline from the Endocrine Society of India suggests either medicine where a 10 to 15% loss is the goal (ESI guideline 2025). For PCOS, the choice usually comes down to how much weight there is to lose, contraception, side effects and pregnancy plans. Our guide to how doctors choose between the two goes through each factor.

Who should not take a GLP-1 medicine

• Women who are pregnant, or trying to conceive in the coming weeks.
• Anyone with a personal or family history of medullary thyroid cancer, or MEN 2 (a boxed warning on both labels).
• Anyone who has had pancreatitis, unless a doctor has weighed it carefully.
• Teenagers with PCOS, outside specialist paediatric care. ALTRcare treats adults only.

A history of an eating disorder also needs an honest conversation first, because medicines that cut appetite can make some patterns worse.